Physician profile
Gil Lichtshein
NPI 1245334622
$10,155.27
in general payments reported to CMS, 2019-2025
18 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $336 · 2021: $1,940 · 2022: $361 · 2023: $6,015 · 2024: $711 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,415 · Food and Beverage: $1,896 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,415.00 |
| Food and Beverage | $1,895.98 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $5,624.69 | 2023-2024 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $1,873.79 | 2019-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $508.34 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $476.84 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $461.88 | 2023-2025 | Auvelity |
| Abbvie INC. | $325.39 | 2021-2024 | |
| Allergan, INC. | $177.52 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $159.54 | 2019-2024 | |
| Alkermes, INC. | $130.53 | 2021-2024 | Lybalvi, Aristada |
| Bausch Health US, LLC | $97.62 | 2019-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $73.67 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.70 | 2022-2023 | |
| Shire North American Group INC | $44.33 | 2019 | |
| Neos Therapeutics, LP | $37.99 | 2024-2025 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $36.09 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.77 | 2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $21.25 | 2025 | Spravato |
| Noven Therapeutics, LLC | $20.33 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Lichtshein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.